Jazz Pharmaceuticals plc

Good day and thank you for standing by. Welcome to Jazz Pharmaceuticals' second quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. Please note that today's conference is being recorded. I will now hand the conference over to your first speaker today, John Bluth, VP and Head of Investor Relations. Please go ahead.

Thank you and good afternoon everyone. Today, Jazz Pharmaceuticals reported its second quarter 2026 financial results. The slide presentation accompanying this webcast is available on the investor section of our website along with the press release and quarterly report on form 10-Q for the second quarter ended June 30, 2026. On the call today are Renee Gala, President and Chief Executive Officer, Sam Pearce, Chief Commercial Officer, Robbie Iannone, Global Head of R&D and Chief Medical Officer, and Phil Johnson, Chief Financial Officer. On slide two, I'd like to remind you that today's webcast includes forward-looking statements such as those related to our future financial and operating results, growth potential and anticipated development, regulatory and commercial milestones, which involve risks and uncertainties that could cause actual events, performance, and results to differ materially from those contained in these forward-looking statements. We encourage you to review these risks and uncertainties described in today's press release and under the caption risk factors in our annual report on Form 10-K for the fiscal year ended December 31st, 2025. We undertake no duty or obligation to update our forward-looking statements. As noted on slide three, we will discuss non-GAAP financial measures on this webcast. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release and the slide presentation available on the investor section of our website. Now, I'd like to turn the call over to Renee.

Thanks, John. Good afternoon, everyone, and thank you for joining today's conference call. We delivered another outstanding quarter, generating record revenue of $1.2 billion, representing 16% year-over-year growth. The momentum we've built in the first half of the year provides us with confidence to raise our full-year revenue guidance. Our results reflect an intense focus on aligned execution across our diversified portfolio, sustained demand of our commercial products, and progress in advancing our long-term priorities for value creation. As we approach a significant milestone with the August 25th Seduca Day for Zany DataMap in first-line HER2-positive metastatic GEA, our commercial, medical, and market access teams are fully prepared to successfully launch Zany DataMap. We're entering a new phase of growth created by the opportunity to deliver clinically meaningful outcomes for patients facing this highly aggressive, difficult to treat disease. Our consistent execution reflects the focus strategy we outlined at the beginning of the year. Expand our leadership in key therapeutic areas, advance differentiated innovation, and create durable long-term value. Across the business, our teams are delivering key therapies to patients advancing Xanidatamab and leveraging our financial strength to invest in both internal R&D and external innovation. An example of this approach is our preclinical research collaboration with Abcelera, which leverages their T-cell engager platform to discover novel multi-specific antibodies. This agreement directly complements our oncology expertise and supports our refined rare disease strategy. These exceptional results from the quarter position us to sustain our momentum while delivering meaningful benefits for patients and driving robust returns for our shareholders. With that, I'll turn the call over to Sam to share more details on our commercial performance.